Format

Send to

Choose Destination
See comment in PubMed Commons below
Helicobacter. 2011 Sep;16 Suppl 1:26-32. doi: 10.1111/j.1523-5378.2011.00877.x.

Inflammation, immunity, and vaccine development for Helicobacter pylori.

Author information

1
Institute of Molecular Cancer Research, University of Zürich, Winterthurerstr 190, 8057 Zurich, Switzerland. mueller@imcr.unizh.ch

Abstract

The immune response to Helicobacter pylori entails both innate effectors and a complex mix of Th1, Th17, and Treg adaptive immune responses. The clinical outcome of infection may well depend to a large degree on the relative balance of these responses. Vaccination with a wide range of antigens, adjuvants, and delivery routes can produce statistically significant reductions in H. pylori colonization levels in mice, though rarely sterilizing immunity. Whether similar reductions in bacterial load can be achieved in humans, and whether they would be clinically significant, is still unclear. However, progress in understanding the role of Th1, Th17, and most recently Treg cells in protection against H. pylori infection provides reason for optimism.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center